06/02/2025 - Press release
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to treatment. The device, which has already been successfully tested on breast cancer samples, could be key to developing new treatments and determining the most appropriate therapy for each patient in a personalized way. The work, published in Nature Communications, is the result of a collaboration between the Institute for Bioengineering of Catalonia and the Research Institute of the Hospital del Mar.
07/02/25 - General information
The Hospital del Mar Research Institute and the company Bionure have signed an agreement to establish a strategic collaboration between the two institutions. The objective is the development of new RNA-based therapies for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The research center will be responsible for conducting proof-of-concept studies for potential medications, both in patient cells and in animal models, which is a necessary step before starting clinical trials in humans. RNA therapies for these types of pathologies are a promising tool not only to slow disease progression but also to potentially repair neuronal damage in neurodegenerative diseases with a genetic component.
03/02/2025 - Institutional news
The latest call for independent research project grants from the Carlos III Health Institute has selected three projects led by researchers from the Hospital del Mar Research Institute. These projects involve three clinical trials in the fields of oncology, nephrology, and neurology. In total, they will receive close to 2.5 million euros.
23/01/2025 - Press release
According to a multicenter study published in the Journal of Hospital Infection, involving twelve hospitals across the country. Patients hospitalized due to healthcare-associated urinary tract infections caused by antibiotic-resistant bacteria require longer hospital stays-an average of three additional days compared to cases caused by bacteria that respond to treatment. The authors warn about the high number of cases caused by resistant bacteria, emphasizing the need to take stricter precautions in the use of antibiotics.
21/01/2025 - Institutional news
Last January 16th, to learn about the work carried out by this pioneering center in Spain. The conseller d'Esportsr, Berni Álvarez, visited the facilities of the Catalonia Anti-Doping Laboratory at the Hospital del Mar Research Institute on January 16th. He was accompanied by the Secretary General of the Sports Department, Abel García, the Director of the Catalan Sports Council, Carme Bastida, and the Head of the Sports and Health Unit of the Catalan Sports Council, Dr. Daniel Brotons.
Més informació "The conseller d’Esports visits the Catalonia Anti-Doping Laboratory"
09/01/2025 - Press release
A multicenter study led by the Hospital del Mar Research Institute identifies five circulating microRNAs in the blood as potential markers for recovery in patients who have suffered a stroke. These small RNA molecules play a significant role in modulating the activity of genes linked to prognosis in ischemic stroke cases. The ability to regulate their activity could pave the way for new treatments to improve outcomes for individuals affected by this condition.
23/12/2024 - Institutional news
The Digestive Tumor Treatment Group (TTD) has awarded one of its grants for research projects on digestive tumors to Dr. Jenniffer Linares, a researcher from the Colorectal Cancer Precision Medicine Research Group, led by Dr. Clara Montagut at the Hospital del Mar Research Institute. The award ceremony took place during the 32nd TTD International Symposium on Advances in Digestive Tumor Treatments. The grant is for the project titled "Clinical impact of CAF-secreted biomarkers in RAS wild-type metastatic CRC patients treated within the CR-SEQUENCE clinical trial." Its goal is to identify the predictive value of biomarkers derived from the tumor microenvironment to anticipate the response to chemotherapy and anti-EGFR treatments in patients with RAS wild-type metastatic colorectal cancer.
Més informació "Grant from the Digestive Tumor Treatment Group for Dr. Jenniffer Linares"
18/12/2024 - Institutional news
At the congress commemorating the institution's tenth anniversary, held in Valencia from November 27 to 29. The PENSA project, driven by the Hospital del Mar Research Institute and the Barcelona βeta Brain Research Center, received one of the awards for the best communications at the congress of the Centro de Investigación Biomédica en Red (CIBERISCIII). This event marked the tenth anniversary of the scientific institution.
Més informació "CIBER Awards the PENSA Project of the Hospital del Mar Research Institute"
17/12/2024 - Press release
Phase 1/2 of the clinical trial shows that the administration of the AEF0217 molecule developed by the biotech Aelis Farma, is safe and can improve key skills such as communication, social interactions and daily living for people with Down syndrome These results reinforce the start of the phase 2 clinical trial, through an international multicenter study with people with Down syndrome, focused on the dose necessary to achieve the treatment goal
16/12/2024 - Institutional news
The work of the Catalonia Anti-Doping Laboratory in the field of innovation and research has been recognized by the Catalan Sports Foundation at the eighth edition of the Sports Awards. The award highlighted the laboratory's research and innovation activities for clean sport, which have earned international recognition. A delegation led by Rosa Ventura, the laboratory's director, and five team members-Sergi Coll, Imma Figuera, Lídia Requena, Susana Cuadras, and Claudia Bressan-attended the award ceremony.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
